TY - JOUR

T1 - Charting the Explicit Path

T2 - Translational Dynamics of Hepatic Bioengineering from Experimental Benchmarks to Practical Bedside Applications

AU - Radhakrishnan, Subathra

AU - Martin, Catherine Ann

AU - Dhayanithy, Geethanjali

AU - Martin, Josette Caroline

AU - Chandrasekaran, Abinaya

AU - Kalkura, Subbaraya Narayana

AU - Rela, Mohamed

PY - 2024

Y1 - 2024

N2 - Liver transplantation is the only optimal method used for treating end-stage liver disease, originated in 1957 and was developed as a mainstream methodology over a span of two decades. Nevertheless, this procedure remains in a state of perpetual evolution, marked by ongoing advancements and adaptations. Moreover, the field of liver transplantation is still baffled by the non-availability of donor livers. Numerous scientific and technical innovations, both direct and tangential to liver transplantation, have emerged, contributing to its refinement, and augmenting the overall progress in this intricate domain. However, many of these findings have not yet been translated into clinical practice. Hepatic bioengineering has become a potential research model that physicians look up to as a treatment option for patients suffering from liver disorders. Research into therapeutic options like cell-based therapy, 3D tissue construction, bioengineering of the liver, and extracorporeal devices for patients who remain at the recipient juncture for a long duration is imperative. Yet, it is a difficult undertaking because the liver is a complex organ that performs several metabolic processes and biotransformation. Additionally, the organ requires continuous perfusion for the delivery of nutrients and oxygen as well as the elimination of waste. Myriad scientific groups are researching bioartificial livers, a supporting device incorporated with metabolically active liver cells to perform liver-specific functions. This review provides current developments in the field of liver regeneration in 2 & 3-dimensional environments and examines each of their pros and cons. It also provides the intersecting points that could be potentially used to overcome various lacunae in the liver transplantation field envisaged using bioengineering as a tool.

AB - Liver transplantation is the only optimal method used for treating end-stage liver disease, originated in 1957 and was developed as a mainstream methodology over a span of two decades. Nevertheless, this procedure remains in a state of perpetual evolution, marked by ongoing advancements and adaptations. Moreover, the field of liver transplantation is still baffled by the non-availability of donor livers. Numerous scientific and technical innovations, both direct and tangential to liver transplantation, have emerged, contributing to its refinement, and augmenting the overall progress in this intricate domain. However, many of these findings have not yet been translated into clinical practice. Hepatic bioengineering has become a potential research model that physicians look up to as a treatment option for patients suffering from liver disorders. Research into therapeutic options like cell-based therapy, 3D tissue construction, bioengineering of the liver, and extracorporeal devices for patients who remain at the recipient juncture for a long duration is imperative. Yet, it is a difficult undertaking because the liver is a complex organ that performs several metabolic processes and biotransformation. Additionally, the organ requires continuous perfusion for the delivery of nutrients and oxygen as well as the elimination of waste. Myriad scientific groups are researching bioartificial livers, a supporting device incorporated with metabolically active liver cells to perform liver-specific functions. This review provides current developments in the field of liver regeneration in 2 & 3-dimensional environments and examines each of their pros and cons. It also provides the intersecting points that could be potentially used to overcome various lacunae in the liver transplantation field envisaged using bioengineering as a tool.

U2 - 10.55828/mrm-21-01

DO - 10.55828/mrm-21-01

M3 - Review

VL - 2

SP - 1

EP - 18

JO - MedLiber of Regenerative Medicine

JF - MedLiber of Regenerative Medicine

IS - 1

ER -